From ASCO: Amgen, Nektar, Sanofi, GRAIL and Others. A Biotech to Keep an Eye on

What Everyone Wants to Hear from ASCO
The American Society of Clinical Oncology (ASCO) meeting is ongoing. What the oncologists, the analysts, the researchers and investors and other interested observers are anxious to hear this year is mostly about the improvements in the immune-oncology approaches.
The Oncologists Want to Hear About:

  • Up-to-date information from clinical trials on immunotherapies in order to practice the safest and most effective immunotherapy approaches;
  • Predictive diagnostic tools that can pinpoint the patients who would benefit from the approved immunotherapy products;
  • The optimal . . .
    This content is for paid subscribers.
    Please click here to subscribe or here to log in.